ROCHE con ATEZOLIZUMAB Registra un Revés en el Estudio de FASE III de Dos Fármacos Contra el Cáncer de Pulmón . Los Datos Detallados Serán Presentados en un Congreso en 2025 .

ROCHE CON ESTE REVES SON YA 30 LOS FRACASOS CON ATEZOLIZUMAB ( TECENTRIQ ) EN  ENSAYOS CLAVES DE FASE III CONTRA EL CÁNCER .

BERLIN, Nov 26 (Reuters) - .

A Roche Study Into Using a Combination of TIRAGOLUMAB and TECENTRIQ ( ATEZOLIZUMAB ) To Treat a Form of Lung Cáncer in a PHASE III Trial Did Not Achieve The Desired Success, The Swiss Pharmaceuticals Maker said on Tuesday .

The SKYSCRAPER-01 STUDY " Did Not Reach The Primary Endpoint Of OVERALL SURVIVAL at The Final Analysis" in Patients With Advanced Or Metastatic Non-Small Cell Lung Cáncer, it Said .

The Detailed Data Will Be Presented At a Medical Meeting in 2025, Added Roche . ...